



FDA Approval Decisions Report August-October 2006

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** – specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

Copyright 2006 by Revere Data, LLC. All rights reserved.

Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

For more information on Revere's independent research data and investment analytics, please contact us as follows:

Revere Data, LLC | 2 Rector Street, Suite 900 | New York, NY 10006
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
Barrier Therapeutics, Inc. (BTRX) / Sebazole (Ketoconazole)				
	Seborrheic Dermatitis	Imidazoles	July 2006	Result Pending
Johnson & Johnson (JNJ) / TetraPeel				
	Local Anesthetic Prior To Surgery	Opioids	July 2006	Result Pending
Johnson & Johnson (JNJ) / Centocor Remicade (Infliximab)				
	Moderate To Severe Plaque Psoriasis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	07/07/2006	Result Pending
MedImmune, Inc. (MEDI) / Cold Adapted Influenza Vaccine-Trivalent (CAIV-T)				
	Influenza Vaccine (Flu Vaccine) In Healthy Individuals 6 Months To 49 Years Of Age	Influenza (Flu)	07/19/2006	Approvable Letter Received 07/18/2006
AstraZeneca PLC (ADR) (AZN) / Symbicort pMDI (Formoterol/Budesonide)				
	Long-Term Maintenance Treatment Of Asthma In Patients 12 Years Of Age And Older	Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)	07/24/2006	Approved 07/21/2006
Encysive Pharmaceuticals, Inc. (ENCY) / Thelin (Sitaxsentan)				
	Pulmonary Arterial Hypertension (PAH)	Endothelin Receptor Antagonists	<u>07/24/2006</u>	Approvable Letter Received 07/24/2006
AVANIR Pharmaceuticals (AVNR) / Neurodex (Dextromethorphan/Quinidine Sulfate)				
	Pseudobulbar Affect (Emotional Lability)	Antitussives/Sodium Channel Blocking Agents	<u>07/28/2006</u>	Rescheduled to 10/30/2006
Enzon Pharmaceuticals, Inc. (ENZN) / Oncaspar (Pegaspargase)				
	First-Line Therapy For Acute Lymphoblastic Leukemia (ALL)	Asparaginases	08/03/2006	Approved 07/24/2006
sanofi-aventis (ADR) (SNY) / Oncaspar (Pegaspargase)				
	First-Line Therapy For Acute Lymphoblastic Leukemia (ALL)	Asparaginases	08/03/2006	Approved 07/24/2006
Shire plc (ADR) (SHPGY) / Elaprase (Idursulfase)				
	Hunter Syndrome (Mucopolysaccharidosis II)	Enzyme Replacement Therapy	<u>08/24/2006</u>	Approved 07/24/2006
Bristol Myers Squibb Co. (BMY) / Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)				
	Human Immunodeficiency Virus (HIV-1) Infection	Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)	02/27/2007	Approved 07/12/2006
Gilead Sciences, Inc. (GILD) / Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)				
	Human Immunodeficiency Virus (HIV-1) Infection	Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)	02/27/2007	Approved 07/12/2006

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.






Expected PDUFA Dates in the Next Three Months

August Drug Candidates

Companies

Abbott Laboratories (ABT)
 Cambridge Antibody Tech. Group plc (ADR) (CATGY)
 Cephalon, Inc. (CEPH)
 Genentech, Inc. (DNA)
 Neurochem Inc. (USA) (NRMX)
 Roche Holding Ltd. (ADR) (RHHBY)
 Salix Pharmaceuticals Ltd (SLXP)

Sectors

I Biopharmaceuticals
 Surgery
 Neurology
 Oncology
 Musculoskeletal System
 Immunology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Salix Pharmaceuticals Ltd (SLXP) / MoviPrep (formerly NRL944)						
	Bowel Cleansing Prior To Colonoscopy, Intestinal Surgery And Barium Enema X-Ray Examinations	Hyperosmotic Agents	<u>08/02/2006</u>	Yes	Yes LiquiPrep / (EZEM) Colyte / (SWTZY)	No
Abbott Laboratories (ABT) / Humira (Adalimumab)						
	Ankylosing Spondylitis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	08/04/2006	Yes	Yes Enbrel/Enbrel Once-Weekly (Etanercept) / (AMGN) Centocor Remicade (Infliximab) / (JNJ)	No
Cambridge Antibody Tech. Group plc (ADR) (CATGY) / Humira (Adalimumab)						
	Ankylosing Spondylitis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	08/04/2006	Yes	Yes Enbrel/Enbrel Once-Weekly (Etanercept) / (AMGN) Centocor Remicade (Infliximab) / (JNJ)	No
Neurochem Inc. (USA) (NRMX) / Fibrillex						
	Amyloid A Amyloidosis (AA Amyloidosis)	Glycosaminoglycan (GAG) Mimetic Agents	<u>08/11/2006</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Genentech, Inc. (DNA) / Herceptin (Trastuzumab)						
	Early Stage, HER2-Positive Breast Cancer	Monoclonal Antibodies	<u>08/17/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (ADR) (RHHBY) / Herceptin (Trastuzumab)						
	Early Stage, HER2-Positive Breast Cancer	Monoclonal Antibodies	<u>08/17/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cephalon, Inc. (CEPH) / Sparlon (Modafinil)						
	Attention Deficit Hyperactivity Disorder (ADHD) In Children And Adolescents Between 6 And 17	Alpha Adrenergic Receptor Agonists	<u>08/22/2006</u>	Yes	Yes SPD 503 / (SHPGY) SPD 465 (Dextroamphetamine/Amphetamine) / (SHPGY)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

September Drug Candidates

Companies

Amgen, Inc. (AMGN)
 AstraZeneca PLC (ADR) (AZN)
 Biogen Idec Inc (BIIB)
 Connetics Corporation (CNCT)
 Eisai Co., Ltd (ADR) (ESALY)
 Genentech, Inc. (DNA)
 GlaxoSmithKline plc (ADR) (GSK)
 Johnson & Johnson (JNJ)
 Labopharm Inc. (DDSS)
 Oscient Pharmaceuticals Corporation (OSCI)
 Pharmion Corporation (PHRM)

Sectors

I Biopharmaceuticals
 Infectious Diseases
 Dermatology
 Pain Management
 Neurology
 Cardiovascular System
 Oncology
 Hematology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
AstraZeneca PLC (ADR) (AZN) / Toprol-XL (Metoprolol Succinate)/Hydrochlorothiazide Combination Therapy						
	Treatment Of Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents	09/01/2006	No	Yes Only Candidate with This PMOA for This Indication	No
GlaxoSmithKline plc (ADR) (GSK) / Altanax (Retapamulin)						
	Uncomplicated Skin And Skin Structure Infections Due To Susceptible Strains Of Staphylococcus aureus And Streptococcus pyogenes	Pleuromutilins	September 2006	No	Yes Only Candidate with This PMOA for This Indication	No
Eisai Co., Ltd (ADR) (ESALY) / Inovelon (Rufinamide)						
	Adjunctive Therapy For Lennox-Gastaut Syndrome (Pediatric Epilepsy), Adjunctive Therapy For Partial-Onset Seizures In Adults And Adolescents	Sodium Channel Blocking Agents	09/14/2006	Yes	Yes Lamictal (Lamotrigine) / (GSK) Trileptal (Oxcarbazepine) / (NVS)	No
Connetics Corporation (CNCT) / Desilux (Desonide)						
	Atopic Dermatitis (Eczema)	Steroidal Anti-Inflammatory Drugs (SAID)	<u>09/21/2006</u>	Yes	Yes Cortizone 5/10 (Hydrocortisone) / (PFE) Synalar (Fluocinolone Acetonide) / (MRX)	No
Oscient Pharmaceuticals Corporation (OSCI) / FACTIVE (Gemifloxacin Mesylate)						
	5 Day Therapy For Mild To Moderate Community-Acquired Pneumonia	Quinolones/Fluoroquinolones	<u>09/21/2006</u>	Yes	Yes Levaquin/Levaquin-Oral (Levofloxacin) / (JNJ)	No
Amgen, Inc. (AMGN) / Vectibix (Panitumumab)						
	Monotherapy For The Treatment Of Metastatic Colorectal Cancer (Colon Cancer) In Patients Who Have Failed Previous Chemotherapy	Monoclonal Antibodies	<u>09/28/2006</u>	Yes	Yes Erbix (Cetuximab) / (IMCL) Avastin (Bevacizumab) / (DNA)	No
Labopharm Inc. (DDSS) / Tramadol Once-Daily						
	Moderate To Severe Pain	Opioids	<u>09/28/2006</u>	Yes	No Multiple Drugs	Yes
Genentech, Inc. (DNA) / Rituxan (Rituximab)						

Company (Symbol) / Drug Candidate						
Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?	
First-Line Treatment Of Indolent Non-Hodgkin's Lymphoma (NHL) In Combination With Or Following CVP/CHOP Chemotherapy	Monoclonal Antibodies	<u>09/29/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No	
Pharmion Corporation (PHRM) / Vidaza (Azacitidine)						
Intravenous Administration To Treat Myelodysplastic Syndromes (MDS), Including Refractory Anemia Or Refractory Anemia With Ringed Sideroblasts, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts In Transformation, And Chronic Myelomonocytic Leukemia (CML)	Pyrimidine Analogs	<u>09/29/2006</u>	Yes	Yes Dacogen (Decitabine) / (MOGN)	No	
Biogen Idec Inc (BIIB) / Rituxan (Rituximab)						
First-Line Treatment Of Indolent Non-Hodgkin's Lymphoma (NHL) In Combination With CVP/CHOP Chemotherapy	Monoclonal Antibodies	<u>09/29/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No	
Johnson & Johnson (JNJ) / Paliperidone ER OROS						
Schizophrenia	Serotonin/Dopamine Receptor Blocking Agents	09/29/2006	Yes	No Multiple Drugs	No	










Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

October Drug Candidates

Companies

AVANIR Pharmaceuticals (AVNR)
 Acambis plc (ADR) (ACAM)
 Adeza Biomedical Corporation (ADZA)
 AstraZeneca PLC (ADR) (AZN)
 BioSante Pharmaceuticals, Inc. (BPA)
 Bradley Pharmaceuticals, Inc. (BDY)
 Eisai Co., Ltd (ADR) (ESALY)
 Forest Laboratories, Inc. (FRX)
 Genentech, Inc. (DNA)
 Genta Incorporated (GNTA)
 GlaxoSmithKline plc (ADR) (GSK)
 MGi Pharma, Inc. (MOGN)
Merck & Co., Inc. (MRK) [2]
 New River Pharmaceuticals, Inc. (NRPH)
 Pfizer Inc. (PFE)
 Replidyne, Inc. (RDYN)
 Roche Holding Ltd. (ADR) (RHHBY)
Schering-Plough Corporation (SGP) [2]
 Sepracor Inc. (SEPR)
Shire plc (ADR) (SHPGY) [2]
 Wyeth (WYE)

Sectors

I Biopharmaceuticals
 Infectious Diseases
 Digestive System
 Respiratory System
 Neurology
 Cardiovascular System
 Oncology
 Immunology
 Obstetrics/Gynecology
 Endocrinology/Metabolism

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
New River Pharmaceuticals, Inc. (NRPH) / NRP104 (Lisdexamfetamine Dimesylate)	Attention Deficit Hyperactivity Disorder (ADHD) In Pediatric Patients 6-12 Years Of Age	Sympathomimetic Agents	<u>10/06/2006</u>	Yes	Yes Dexedrine (Dextroamphetamine Sulfate) / (GSK)	Yes
Shire plc (ADR) (SHPGY) / NRP104 (Lisdexamfetamine Dimesylate)	Attention Deficit Hyperactivity Disorder (ADHD) In Pediatric Patients 6-12 Years Of Age	Sympathomimetic Agents	<u>10/06/2006</u>	Yes	Yes Dexedrine (Dextroamphetamine Sulfate) / (GSK)	No
Merck & Co., Inc. (MRK) / Zolinza (Vorinostat)	Cutaneous T-Cell Lymphoma (Non-Hodgkin's Lymphoma (NHL))	Histone Deacetylase (HDAC) Inhibitors	10/06/2006	No	Yes Only Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)	First-Line Treatment Of Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapies	Monoclonal Antibodies	<u>10/11/2006</u>	Yes	Yes Erbitux (Cetuximab) / (BMY) Erbitux (Cetuximab) / (IMCL)	No
Genentech, Inc. (DNA) / Avastin (Bevacizumab)	First-Line Treatment Of Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapies	Monoclonal Antibodies	<u>10/11/2006</u>	Yes	Yes Erbitux (Cetuximab) / (BMY) Erbitux (Cetuximab) / (IMCL)	No
Sepracor Inc. (SEPR) / Arformoterol	Chronic Obstructive Pulmonary Disease (COPD)	Beta Adrenergic Receptor Agonists	<u>10/12/2006</u>	Yes	Yes Foradil Aerolizer (Formoterol) / (SGP) Serevent (Salmeterol Xinafoate) / (GSK)	No
MGi Pharma, Inc. (MOGN) / Saforis (L-Glutamine)	Oral Mucositis Associated With Mucotoxic Cancer Therapy	Immunomodulatory Agents	<u>10/12/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Schering-Plough Corporation (SGP) / Garenoxacin						
	Broad Spectrum Antibiotics For Both Gram-Positive And Gram-Negative Bacterial Pathogens	Macrolides	10/13/2006	Yes	No Multiple Drugs	No
BioSante Pharmaceuticals, Inc. (BPA) / BioE-Gel (Estradiol Gel)						
	Moderate-To-Severe Hot Flashes In Menopausal Women	Estrogens	10/16/2006	Yes	No Multiple Drugs	Yes
Pfizer Inc. (PFE) / Aricept (Donepezil Hydrochloride)						
	Severe Alzheimer's Disease	Acetylcholinesterase Inhibitors	10/16/2006	Yes	Yes Only Candidate with This PMOA for This Indication	No
Eisai Co., Ltd (ADR) (ESALY) / Aricept (Donepezil Hydrochloride)						
	Severe Alzheimer's Disease	Acetylcholinesterase Inhibitors, Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators	10/16/2006	Yes	Yes Only Candidate with This PMOA for This Indication	No
Merck & Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)						
	Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/16/2006	No	Yes Galvus (Vildagliptin) / (NVS)	No
Acambis plc (ADR) (ACAM) / Smallpox-ACAM2000						
	Smallpox Vaccine	Variola (Smallpox)	10/18/2006	No	Yes Only Candidate with This PMOA for This Indication	No
Adeza Biomedical Corporation (ADZA) / Gestiva						
	Preterm Birth Prevention In Women With A History Of Preterm Delivery	Progestins	10/20/2006	Yes	Yes Crinone/Prochieve 8% (Progesterone) / (CBRX)	Yes
Forest Laboratories, Inc. (FRX) / Orapem (Faropenem Medoxomil)						
	Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, Uncomplicated Skin And Skin Structure Infections In Adults	Carbapenems	10/20/2006	Yes	Yes Invanz (Ertapenem Sodium) / (MRK)	No
Replidyne, Inc. (RDYN) / Orapem (Faropenem Medoxomil)						
	Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, Uncomplicated Skin And Skin Structure Infections In Adults	Carbapenems	10/20/2006	Yes	Yes Invanz (Ertapenem Sodium) / (MRK)	Yes
Shire plc (ADR) (SHPGY) / Mesavance/SPD 476 (Mesalamine)						
	Mild-To-Moderate Ulcerative Colitis	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	10/23/2006	Yes	No Multiple Drugs	No
Wyeth (WYE) / Desvenlafaxine Succinate/DVS-233						
	Major Depressive Disorder	Selective Norepinephrine Reuptake Inhibitors (SNRI)	10/23/2006	Yes	Yes Pamelor (Nortriptyline Hydrochloride) / (TYC)	No
Schering-Plough Corporation (SGP) / Noxafil (Posaconazole)						

Company (Symbol) / Drug Candidate						
Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?	
Oropharyngeal Candidiasis (OPC)	Imidazoles	10/23/2006	Yes	Yes Only Candidate with This PMOA for This Indication	No	
GlaxoSmithKline plc (ADR) (GSK) / Coreg CR (Carvedilol Controlled Release)						
Once Daily Dose For Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	10/23/2006	Yes	No Multiple Drugs	No	
Genta Incorporated (GNTA) / Genasense (Oblimersen Sodium)						
Chronic Lymphocytic Leukemia (CLL) In Combination With Fludarabine and Cyclophosphamide	Antisense Agents	<u>10/27/2006</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No	
AVANIR Pharmaceuticals (AVNR) / Neurodex (Dextromethorphan/Quinidine Sulfate)						
Pseudobulbar Affect (Emotional Lability)	Antitussives/Sodium Channel Blocking Agents	<u>10/30/2006</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes	
AstraZeneca PLC (ADR) (AZN) / Seroquel (Quetiapine Fumarate)						
Bipolar Depression	Monoaminergic Antagonists	10/30/2006	Yes	Yes Zyprexa (Olanzapine) / (LLY) Risperdal/Risperdal Consta (Risperidone) / (JNJ)	No	
Bradley Pharmaceuticals, Inc. (BDY) / Polyphenon E Ointment						
Genital Warts	Catechins	<u>10/31/2006</u>	No	Yes Only Candidate with This PMOA for This Indication	No	

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

Price and Financial Info

August 2006

Data as of 07/28/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. Δ BPHRM
Abbott Laboratories	ABT	47.82	72,983.691	5,902,540	n/a	n/a	n/a	2.14%	4.87%
Cephalon, Inc.	CEPH	66.04	4,011.207	2,123,435	n/a	224.07	541.5	54.48%	57.22%
Genentech, Inc.	DNA	80.14	84,437.664	3,906,840	n/a	n/a	n/a	-9.88%	-7.15%
Cambridge Antibody Tech. Group plc (ADR)	CATGY	24.41	1,293.146	4,796	4.06	0.14	302.9	99.27%	102.00%
Roche Holding Ltd. (ADR)	RHHBY	87.40	150,775.923	n/a	8.11	24.11	16,360.1	27.50%	30.23%
Salix Pharmaceuticals Ltd	SLXP	10.18	473.585	439,565	3.06	0.14	59.1	-46.98%	-44.24%
Neurochem Inc. (USA)	NRMX	10.21	394.560	88,813	11.51	0	53.6	-9.65%	-6.91%

Definitions: **Market Cap.** - Market Capitalization, **Price To Tang. Book Value** - Price to Tangible Book Value, **Cash & Equiv.+ ST Inv.** - Cash and Equivalents + Short-Term Investments, **Rel. Perf. vs. Δ BPHRM** - Relative Performance vs. Revere Biopharm Index,

September 2006

Data as of 07/28/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. Δ BPHRM
Amgen, Inc.	AMGN	69.07	80,811.901	8,189,888	48.56	53.45	4,970.0	-14.73%	-11.99%
Connetics Corporation	CNCT	9.80	337.195	1,362,325	3.27	281.15	224.1	-47.57%	-44.83%
Genentech, Inc.	DNA	80.14	84,437.664	3,906,840	n/a	n/a	n/a	-9.88%	-7.15%
Oscient Pharmaceuticals Corporation	OSCI	0.86	82.626	517,261	n/a	1,811.28	52.3	-66.67%	-63.93%
GlaxoSmithKline plc (ADR)	GSK	55.62	161,388.593	1,082,671	17.66	61.64	8,909.7	16.73%	19.46%
Biogen Idec Inc	BIIB	41.84	14,387.199	3,102,510	4.79	0	713.8	4.86%	7.60%
Johnson & Johnson	JNJ	62.92	186,307.756	6,745,672	n/a	n/a	n/a	-2.80%	-0.06%
AstraZeneca PLC (ADR)	AZN	60.85	95,412.797	1,152,936	9.26	7.59	7,096.0	37.86%	40.59%
Eisai Co., Ltd (ADR)	ESALY	47.10	13,462.253	n/a	3.40	0.09	1,341.6	35.93%	38.67%
Pharmion Corporation	PHRM	17.15	549.525	238,864	2.54	0	185.1	-30.87%	-28.14%
Labopharm Inc.	DDSS	6.20	350.963	70,645	n/a	0	21.7	n/a	

Definitions: **Market Cap.** - Market Capitalization, **Price To Tang. Book Value** - Price to Tangible Book Value, **Cash & Equiv.+ ST Inv.** - Cash and Equivalents + Short-Term Investments, **Rel. Perf. vs. Δ BPHRM** - Relative Performance vs. Revere Biopharm Index,

October 2006

Data as of 07/28/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. Δ BPHRM
Wyeth	WYE	48.86	65,763.070	5,549,776	n/a	n/a	n/a	6.73%	9.46%
Bradley Pharmaceuticals, Inc.	BDY	10.19	176.031	312,048	n/a	43.94	16.7	-8.28%	-5.54%
Forest Laboratories, Inc.	FRX	46.61	14,941.618	2,604,640	n/a	n/a	n/a	15.72%	18.45%
Genentech, Inc.	DNA	80.14	84,437.664	3,906,840	n/a	n/a	n/a	-9.88%	-7.15%
Genta Incorporated	GNTA	1.58	211.197	1,746,330	4.78	0.63	47.2	33.90%	36.63%
GlaxoSmithKline plc (ADR)	GSK	55.62	161,388.593	1,082,671	17.66	61.64	8,909.7	16.73%	19.46%
Merck & Co., Inc.	MRK	41.12	89,744.687	10,920,710	n/a	n/a	n/a	31.42%	34.15%
MGi Pharma, Inc.	MOGN	15.01	1,172.383	1,781,048	n/a	n/a	n/a	-43.76%	-41.03%
Pfizer Inc.	PFE	26.11	191,318.163	26,071,404	n/a	n/a	n/a	-2.47%	0.27%
Schering-Plough Corporation	SGP	20.75	30,731.786	6,172,008	n/a	n/a	n/a	-1.24%	1.50%
Sepracor Inc.	SEPR	48.66	5,291.746	2,801,632	n/a	0	944.5	-8.71%	-5.97%
Shire plc (ADR)	SHPGY	46.98	7,839.801	458,210	9.86	0	843.9	34.34%	37.08%
AstraZeneca PLC (ADR)	AZN	60.85	95,412.797	1,152,936	9.26	7.59	7,096.0	37.86%	40.59%

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Wyeth	WYE	48.86	65,763.070	5,549,776	n/a	n/a	n/a	6.73%	9.46%
Eisai Co., Ltd (ADR)	ESALY	47.10	13,462.253	n/a	3.40	0.09	1,341.6	35.93%	38.67%
AVANIR Pharmaceuticals	AVNR	6.85	216.979	341,955	6.84	2.32	49.7	-48.42%	-45.68%
Acambis plc (ADR)	ACAM	5.45	292.533	12,035	2.49	13.49	125.4	-33.94%	-31.20%
Roche Holding Ltd. (ADR)	RHHBY	87.40	150,775.923	n/a	8.11	24.11	16,360.1	27.50%	30.23%
BioSante Pharmaceuticals, Inc.	BPA	1.98	45.488	124,029	9.69	0	7.1	-50.99%	-48.25%
New River Pharmaceuticals, Inc.	NRPH	24.35	891.869	237,752	313.05	1.54	95.0	44.21%	46.95%
Adeza Biomedical Corporation	ADZA	15.29	266.853	190,949	2.71	0	90.5	-7.45%	-4.71%
Replidyne, Inc.	RDYN	10.03	265.093	131,543	n/a	n/a	n/a	n/a	

Definitions: **Market Cap.** - Market Capitalization, **Price To Tang. Book Value** - Price to Tangible Book Value, **Cash & Equiv.+ ST Inv.** - Cash and Equivalents + Short-Term Investments, **Rel. Perf. vs. ^BPHRM** - Relative Performance vs. Revere Biopharm Index,